NCI-Led Trial to Test EGFR as Marker for Lung Cancer Drug Response

Oct 02, 2008

NEW YORK (GenomeWeb News) – The National Cancer Institute said today that it is starting an initiative to validate if a biomarker can predict the clinical benefit of a chemotherapy drug for non-small cell lung cancer in certain patients.

The study, called Marker Validation for Erlotinib in Lung Cancer, or MARVEL, will seek to find out if there is value in choosing patients for treatment with the drug based on the presence or absence of EGFR activation.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Breaking News

The Scan

The Same Genes Keep Getting Asked to Prom

Researchers find that historical factors influence which genes are the most highly studied, the Atlantic reports.

Keep Them in the Know

The US National Science Foundation's new sexual harassment policy is to go into effect next month, according to Nature News.

From Tusk to Cartel

Researchers report using genotyping to tie together illegal ivory shipments and trace them back to a handful of cartels, the New York Times reports.

This Week in Nature

In Nature this week: genomic ancestry analysis of Sardinians, current noncoding mutations in colorectal cancer, and more.

Main menu